EGFR and non-small cell lung carcinoma: The improved clinical outcomes found in the literature and the positive result obtained in the present case suggest the utility of neoadjuvant EGFR-TKI in NSCLC, even in lung adenoaquamous carcinoma patients harboring EGFR mutation.